Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral encapsulated GLP-1 receptor agonist
- Development stage
- Preclinical
- Lead developer
- Poolbeg Pharma
- Modality
- Peptides
- Administration
- Oral
01
Overview
Poolbeg Pharma is developing an oral encapsulated GLP-1 receptor agonist for the treatment of obesity and metabolic diseases. The program utilizes proprietary microencapsulation and nanoencapsulation oral delivery technology licensed from InsuCaps Limited to deliver GLP-1 receptor agonist peptides orally. The technology uses a pH-sensitive release mechanism to deliver the peptide to specific areas of the gut, aiming to enhance bioavailability and provide a more convenient alternative to injectable GLP-1 treatments. The drug targets the GLP-1 receptor to promote satiety and weight loss. Poolbeg Pharma is progressing toward a proof-of-concept clinical trial, with topline data expected in the first half of 2026.
- Other names
- Oral Encapsulated GLP-1
02
Targets
Beyond the preview
Go deeper on oral encapsulated GLP-1 receptor agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral encapsulated GLP-1 receptor agonist.